140 related articles for article (PubMed ID: 17042469)
41. Innate Valpha14(+) natural killer T cells mature dendritic cells, leading to strong adaptive immunity.
Fujii S; Shimizu K; Hemmi H; Steinman RM
Immunol Rev; 2007 Dec; 220():183-98. PubMed ID: 17979847
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and in vivo evaluation of 4-deoxy-4,4-difluoro-KRN7000.
Leung L; Tomassi C; Van Beneden K; Decruy T; Elewaut D; Elliott T; Al-Shamkhani A; Ottensmeier C; Van Calenbergh S; Werner J; Williams T; Linclau B
Org Lett; 2008 Oct; 10(20):4433-6. PubMed ID: 18798635
[TBL] [Abstract][Full Text] [Related]
43. Concise synthesis of α-galactosyl ceramide from D-galactosyl iodide and D-lyxose.
Yen YF; Kulkarni SS; Chang CW; Luo SY
Carbohydr Res; 2013 Mar; 368():35-9. PubMed ID: 23333444
[TBL] [Abstract][Full Text] [Related]
44. Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease.
Benoit AC; Huang Y; Maneewatchararangsri S; Tapchaisri P; Anderson R
Vaccine; 2007 Nov; 25(45):7754-62. PubMed ID: 17920164
[TBL] [Abstract][Full Text] [Related]
45. Structure-activity relationship of alpha-galactosylceramides against B16-bearing mice.
Morita M; Motoki K; Akimoto K; Natori T; Sakai T; Sawa E; Yamaji K; Koezuka Y; Kobayashi E; Fukushima H
J Med Chem; 1995 Jun; 38(12):2176-87. PubMed ID: 7783149
[TBL] [Abstract][Full Text] [Related]
46. RCAI-37, 56, 59, 60, 92, 101, and 102, cyclitol and carbasugar analogs of KRN7000: their synthesis and bioactivity for mouse lymphocytes to produce Th1-biased cytokines.
Tashiro T; Nakagawa R; Hirokawa T; Inoue S; Watarai H; Taniguchi M; Mori K
Bioorg Med Chem; 2009 Sep; 17(17):6360-73. PubMed ID: 19656685
[TBL] [Abstract][Full Text] [Related]
47. Invariant natural killer T cells: innate-like T cells with potent immunomodulatory activities.
Wu L; Gabriel CL; Parekh VV; Van Kaer L
Tissue Antigens; 2009 Jun; 73(6):535-45. PubMed ID: 19392798
[TBL] [Abstract][Full Text] [Related]
48. Valpha14 NKT cells activated by alpha-galactosylceramide augment lipopolysaccharide-induced nitric oxide production in mouse intra-hepatic lymphocytes.
Ohtaki H; Ito H; Ando K; Ishikawa T; Saito K; Imawari M; Yokochi T; Moriwaki H; Seishima M
Biochem Biophys Res Commun; 2009 Jan; 378(3):579-83. PubMed ID: 19056341
[TBL] [Abstract][Full Text] [Related]
49. C-Glycosphingolipids with an exo-methylene substituent: stereocontrolled synthesis and immunostimulation of mouse and human natural killer T lymphocytes.
Liu Z; Courtney AN; Metelitsa LS; Bittman R
Chembiochem; 2012 Aug; 13(12):1733-7. PubMed ID: 22782839
[No Abstract] [Full Text] [Related]
50. Synthesis of BC-ring model of globostellatic acid X methyl ester, an anti-angiogenic substance from marine sponge.
Kotoku N; Tamada N; Hayashi A; Kobayashi M
Bioorg Med Chem Lett; 2008 Jun; 18(12):3532-5. PubMed ID: 18492609
[TBL] [Abstract][Full Text] [Related]
51. C-Galactosylceramide: Synthesis and Immunology.
Franck RW
C R Chim; 2012 Jan; 15(1):46-56. PubMed ID: 22408579
[TBL] [Abstract][Full Text] [Related]
52. Enhancement of HIV DNA vaccine immunogenicity by the NKT cell ligand, alpha-galactosylceramide.
Huang Y; Chen A; Li X; Chen Z; Zhang W; Song Y; Gurner D; Gardiner D; Basu S; Ho DD; Tsuji M
Vaccine; 2008 Mar; 26(15):1807-16. PubMed ID: 18329757
[TBL] [Abstract][Full Text] [Related]
53. Prophylaxis of lipopolysaccharide-induced shock by alpha-galactosylceramide.
Sireci G; La Manna MP; Di Liberto D; Lo Dico M; Taniguchi M; Dieli F; Salerno A
J Leukoc Biol; 2008 Aug; 84(2):550-60. PubMed ID: 18458153
[TBL] [Abstract][Full Text] [Related]
54. Activation of invariant natural killer T cells by synthetic glycolipid ligands suppresses autoantibody-induced arthritis.
Kaieda S; Tomi C; Oki S; Yamamura T; Miyake S
Arthritis Rheum; 2007 Jun; 56(6):1836-45. PubMed ID: 17530712
[TBL] [Abstract][Full Text] [Related]
55. Effects of cyclosporin A on the activation of natural killer T cells induced by alpha-galactosylceramide.
Kajiwara T; Tomita Y; Okano S; Iwai T; Yasunami Y; Yoshikai Y; Nomoto K; Yasui H; Tominaga R
Transplantation; 2007 Jan; 83(2):184-92. PubMed ID: 17264815
[TBL] [Abstract][Full Text] [Related]
56. Hyporesponsiveness to natural killer T-cell ligand alpha-galactosylceramide in cancer-bearing state mediated by CD11b+ Gr-1+ cells producing nitric oxide.
Yanagisawa K; Exley MA; Jiang X; Ohkochi N; Taniguchi M; Seino K
Cancer Res; 2006 Dec; 66(23):11441-6. PubMed ID: 17145891
[TBL] [Abstract][Full Text] [Related]
57. Pivotal advance: alpha-galactosylceramide induces protection against lipopolysaccharide-induced shock.
Sireci G; La Manna MP; Di Sano C; Di Liberto D; Porcelli SA; Kronenberg M; Dieli F; Salerno A
J Leukoc Biol; 2007 Mar; 81(3):607-22. PubMed ID: 17046969
[TBL] [Abstract][Full Text] [Related]
58. Synthesis of C-glycoside analogues of α-galactosylceramide via linear allylic C-H oxidation and allyl cyanate to isocyanate rearrangement.
Liu Z; Bittman R
Org Lett; 2012 Jan; 14(2):620-3. PubMed ID: 22233351
[TBL] [Abstract][Full Text] [Related]
59. Activation-induced NKT cell hyporesponsiveness protects from alpha-galactosylceramide hepatitis and is independent of active transregulatory factors.
Biburger M; Tiegs G
J Leukoc Biol; 2008 Jul; 84(1):264-79. PubMed ID: 18407967
[TBL] [Abstract][Full Text] [Related]
60. Mediastinal lymph node CD8alpha- DC initiate antigen presentation following intranasal coadministration of alpha-GalCer.
Ko SY; Lee KA; Youn HJ; Kim YJ; Ko HJ; Heo TH; Kweon MN; Kang CY
Eur J Immunol; 2007 Aug; 37(8):2127-37. PubMed ID: 17615581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
